1. 19/05/2018
An introduction to Horizon Scanning Research & Intelligence Centre (HSRIC)

2. 19/05/2018
Aims: to provide advance notice to the Department of Health (England), health service policy-making bodies and research funders of significant new and emerging technologies, up to 3 years prior to launch on the NHS, that need:
further research or evaluation,
consideration of clinical and cost effectiveness
consideration of cost impact
consideration of implementation requirements
modification of clinical guidelines
Remit:
Pharmaceuticals (new drugs and new indications of existing drugs), devices, diagnostic tests and procedures, surgical and other interventions, rehabilitation, public health and health promotion activities.

3. Drug team structure Dr Claire Packer Director Dr Sue Simpson
Dr Ali Cook
Associate Director
MedTech team lead
Dr Sue Simpson
Associate Director
Reviews team lead
Dr Derek Ward
Drugs team Medical advisor
Kathryn Miles
Senior Analyst
Dr Luan Linden Phillips
Senior Analyst
6 Horizon Analysts

4. 19/05/2018
Topics covered
All interventions which are used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. Including:
Pharmaceuticals – phase II, III and pre-launch
Ideally months notice prior to licensing
Medical devices, implants, biomaterials etc - prior to, or within 2 years of marketing or marketed but <10% diffused or localised to a few centres
Diagnostic tests and procedures
Interventional procedures
Public health and screening programmes
Rehabilitation and other therapy

5. Methods: identification sources
Scientific journals
Commercial developers
Trial registries
Other horizon scanning organisations
New or emerging health technologies
Medical media
General media
Clinical experts
Commercial media
Patients and public

6. Euroscan: www.euroscan.org.uk
19/05/2018
18 worldwide member agencies
Information exchange
Methodology exchange

7. Initial filtration of pharmaceuticals
19/05/2018
Initial filtration of pharmaceuticals
Consider:
Appropriateness for the NHS
Innovation
Potential for clinical benefit
Potential for high cost
Government priority areas; no cancer drugs excluded
The first biosimilar for each indication
Exclude:
HIV products and prophylactic vaccines (remit of other agencies)
Generics and subsequent biosimilars

8. Prioritisation of pharmaceuticals
19/05/2018
Prioritisation of pharmaceuticals
Based on anticipated licensing / launch timeframe:
Quarter/year of possible licensing (or launch)
New drugs, minimum of 20 months notice to NICE
New indications for existing drugs, minimum of 15 months notice to NICE
Place in clinical development - phase II or III trials
Reporting date of ongoing trials

9. Working together to improve NHS planning for new medicines

10. Maintains confidentiality Collaboration engagement with stakeholders
Benefits
Reduces duplication
Ensures consistency
Corporate reputation
Champion user
Productivity
Maintains confidentiality
Relevance
Improves standards
Responsive
Collaboration engagement with stakeholders

11. Intelligence on new medicines and new indications
Complete and accurate information to avoid duplication of effort
Confidentiality and security:
Secure safeguards are in place to control access
Access only to registered pharmaceutical companies and national horizon scanning organisations
All organisations granted access are required to sign a user agreement that sets out roles and responsibilities, including strict adherence to commercial confidentiality
To register go to and complete the online registration form

12. NICE Topic Selection process
Reject or refer elsewhere (MPC / NICE Guidelines)
NICE Guidance produced
NIHR Horizon Scanning Research and Intelligence Centre
Decision Point 1/2 for TA or HST programme

13. Filtration forms – scoring Will NICE Guidance add value?
19/05/2018
Filtration forms – scoring Will NICE Guidance add value?
Population (1-5) The larger the population, the more important a technology is for evaluation.
Disease severity (1-5) Severity of condition impacts on importance of evaluation; takes into account: life expectancy; how far the individual is away from perfect health and health states that incur social stigma.
Resource impact (1-5) Potential resource impact of guidance including cost of implementing guidance, including any additional service, facilities or staff requirements.
Claimed Therapeutic benefit (1-5) Extent to which a new technology claims measurable therapeutic benefit over currently available NHS treatments.

14. 19/05/2018
Topics reaching NICE
Transparent reporting of topic progress on the NICE website:
Available for topic selection from January 2015, HST to follow.
Updated as topics progress through scoping
Timings at NICE
Generally one week after a briefing arrives with NICE, the company get a letter from NICE.
If the topic reaches NICE two years or more before launch, a scoping workshop normally takes place at NICE one year before licence.

15. Technology briefing Technology, marketing plans and timing
19/05/2018
Technology briefing
Technology, marketing plans and timing
Indication, patient group size, epidemiology
Current treatment, service usage
Current guidance and guidelines
Ongoing and published research
Assessment of clinical and resource impact, place in patient pathway

16. 19/05/2018
Drugs team customers
NIHR HSRIC
NICE Technology Appraisals
NICE Technology Appraisals for Highly specialised technologies
Department of Health policy teams
NHS England
All non-confidential versions of briefings are published on our website

17. Drugs team collaborators
19/05/2018
Drugs team collaborators
NIHR HSRIC
NICE Medicines and Prescribing Centre (MPC)
UK Medicines Information (UKMI)
Scottish Medicines Consortium
NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC)
Department of Health, Northern Ireland
All Wales Medicines Strategy Group (AWMSG)
Research and Development Directorate at the Department of Health

18. Principal information flows for HSRIC

19. Company contacts – HSRIC approach
HTAi workshop 6th June 2010
Company contacts – HSRIC approach
Exchange information
Role and function of HSRIC and other relevant agencies
Development stage, patient indications & regulatory plans/timelines for all company products
Identify other product(s) not previously identified through scanning or prior company contacts
Remove discontinued/obsolete products
Request information
Individual product(s) identified through other routine scanning or prior company contacts
To support initial filtration, prioritisation or later preparation of full briefing outputs
Development stage, patient indications & regulatory plans/timelines
Around 140 companies about 220 technologies a quarter
Generally one primary contact at each company
Company pipeline meeting
Other company contact

20. Patient & Public Involvement at HSRIC
We aim to:
To identify areas of work where we can build and strengthen mutually advantageous relationships
Ensure accessibility and effective dissemination of outputs
Avoid tokenism
Add value
PPI for the drugs team:
Piloting patient comments on two briefings in 2014/2015
Developing lay summaries in 2015
Broader PPI at HSRIC detailed in our activity report and strategy at:

21. NIHR HSRIC website http://www.hsric.nihr.ac.uk/

22. Confidentiality The HSRIC undertakes to:
19/05/2018
Confidentiality
The HSRIC undertakes to:
Keep all Confidential Information strictly confidential;
Not use any Confidential Information for any purpose other than participating in the HSRIC’s processes;
Restrict access to any Confidential Information to only those persons that need to know such information.
Not disclose any Confidential Information to any third party other than for the purposes outlined in the text above, and where the third party is fully aware of the Confidential Information and agrees to be bound by these undertakings.
Full confidentiality statement is available at: